immunoaffinity mass spectrometry

The company plans to offer the immuno-MRM assays as kits covering sample prep and protein digestion as well as immuno-enrichment of specific peptides.

The company, called SISCAPA Assay Technologies, will offer assay development to pharmas and CROs and has tapped antibody firm Epitomics to produce reagents for the system and sell SISCAPA kits. So far, the company has licensed the technology to Pfizer for internal use.

The technique is useful for monitoring protein biomarkers in order to better understand target pathways and molecules as well building pharmacokinetic and pharmacodynamic models, said a company scientist.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.